The heat-labile enterotoxin (LT) of enterotoxigenic Escherichia coli is structurally similar to cholera toxin (CT) produced by Vibrio cholerae, and both toxins act as adjuvants for enhancement of mucosal and serum antibody responses to coadministered protein antigens given either orally or nasally [1] [2] [3] . CT acts as adjuvant by inducing CD4 ϩ Th2 cells that secrete interleukin (IL)-4, IL-5, IL-6, and IL-10, which provide help for antigen-specific secretory IgA (sIgA) as well as serum IgG1, IgA, and IgE antibody responses in mouse models [4, 5] . CT has also been shown to selectively inhibit proliferation of mouse CD4 ϩ Th1, but not Th2, cell lines stimulated by anti-CD3 monoclonal antibody (MAb) or by phorbol myristate acetate and ionomycin [6] . On the other hand, mucosal immunization of mice with antigen and LT induced mixed CD4
ϩ Th1-and Th2-type cells with subsequent mucosal sIgA antibody responses [7] . However, the molecular basis for induction of antigen-specific CD4 ϩ Th1 and Th2 cells and for regulation of the mucosal IgA antibody responses by the mucosal adjuvant LT is unknown.
IL-4 induces the differentiation of T cells into a Th2 phenotype, which provides effective help for B cells, most notably for IgG1, IgE, and IgA antibody responses [8] [9] [10] . Furthermore, oral administration of protein antigen plus CT to IL-4 gene-disrupted (IL-4 Ϫ/Ϫ ) mice failed to elicit antigen-specific sIgA antibodies, even though the mice exhibited normal levels of IgA in external secretions and of IgA plasma cells in the lamina propria of the gastrointestinal tract [11] [12] [13] . Thus, although IgA responses were not totally dependent on IL-4, the CT-induced adjuvant responses were clearly the result of CD4 ϩ Th2-type cells. On the other hand, it has been shown that several other Th2-type cytokines (e.g., IL-5, IL-6, and IL-10) are associated with sIgA antibody responses [14] [15] [16] [17] [18] . For example, oral immunization with recombinant Salmonella expressing fragment C of tetanus toxin induces antigen-specific Th1 and selected Th2 (IL-6 and IL-10) cytokines, with subsequent sIgA responses, in the absence of IL-4 [12, 19] .
CD28 on T cells provides a potent costimulatory signal after interactions with B7-1 (CD80) and B7-2 (CD86) expressed on antigen-presenting cells (APC) [20] . With regard to the involvement of CD28/B7 cosignaling in the adjuvanticity of CT, it has been reported that both native CT and a fusion protein with the intact A1 subunit enhanced B7-1 and B7-2 expression on B cells [21] . In contrast, other studies have shown that CT enhances B7-2, but not B7-1, expression by macrophages, and administration of anti-B7-2 MAbs inhibited keyhole limpet hemocyanin (KLH)-specific serum IgG and mucosal IgA antibody responses in mice given KLH plus CT orally [22] . Our recent studies have shown that nontoxic mutant CT mainly induces B7-2 on mucosal B cells and macrophages that in turn leads to increased proliferative responses of CD4 ϩ T cells in the presence of anti-CD3 stimulation [23] . These studies raise the interesting possibility that LT and CT differ in their effects on costimulatory molecule expression by APC for subsequent Th1-or Th2-type responses.
Thus, several lines of evidence indicate that LT differs from CT for induction of mucosal adjuvanticity. The present study was done to elucidate differences in the cytokine patterns elicited by these enterotoxins.
Materials and Methods

Mice. IL-4 gene-disrupted (IL-4
Ϫ/Ϫ ) C57BL/6 mice were produced as described previously [11] . Control wild-type (IL-4 ϩ/ϩ ) C57BL/6 mice were purchased from Jackson Laboratory Animal Resources Center (West Grove, PA). CD40 gene knockout (CD40 Ϫ/Ϫ ) mice were provided by Kenji Yoshida and Hitoshi Kikutani (Osaka University, Osaka, Japan). These mice were maintained and bred under pathogen-free conditions in the University of Alabama at Birmingham Immunobiology Vaccine Center and at the Research Institute for Microbial Diseases, Osaka University. All mice were provided sterile food and water ad libitum and were used in this study at 8-12 weeks of age.
Antigens and adjuvants. Recombinant (r) LT was prepared and purified as described elsewhere [24] . In brief, E. coli HB101 containing the plasmid pKTN1003b, which harbors the LT gene, was grown in LB medium (10 mg/mL NaCl, 10 mg/mL tryptone, 5 mg/ mL yeast extract) with 100 mg/mL ampicillin. LT was purified by use of a D-galactose-immobilized column (Pierce, Rockford, IL) from a cell suspension prepared by sonication. Vaccine-grade tetanus toxoid (TT) was provided by Patricia J. Freda Pietrobon (Connaught Laboratories, Swiftwater, PA) and Masahiko Mutai (Research Foundation for Microbial Diseases, Osaka University). CT was purchased from List Biologic Laboratories (Campbell, CA) and ovalbumin from Sigma (St. Louis).
Immunization protocols. Mice were deprived of food for 2 h and given 0.25 mL of an isotonic solution containing 8 parts of Hanks' balanced saline solution and 2 parts of 7.5% sodium bicarbonate by gastric intubation to neutralize stomach acidity. After 30 min, mice were intubated orally with 0.2 mL of PBS containing a mixture of TT (250 mg/mouse) and LT (10 mg/mouse) or CT (10 mg/mouse). Groups of mice were immunized on days 0, 7, and 14 [25] . In some experiments, mice were orally immunized with ovalbumin (1 mg/mouse) together with either LT or CT (10 mg/mouse) as adjuvant at the same intervals.
Purification of CD4 ϩ T cells and T cell depletion. CD4 ϩ T cells from Peyer's patch cell suspensions were purified by use of the magnetic activated cell sorter system (Miltenyi Biotec, Sunnyvale, CA). In brief, cells were added to a nylon wool column (Polysciences, Warrington, PA) and incubated at 37ЊC for 1 h to remove adherent cells. The enriched T cell populations were then incubated with biotinylated anti-CD8 (53-6.7), anti-Mac-1 (M1/70), and anti-B220 (RA3-6A2) MAbs followed by streptavidin-conjugated microbeads before being passed through the magnetic column. Two cycles of the above procedures yielded CD4 ϩ T cell preparations of 198% purity. To obtain T cell-depleted Peyer's patch cells, T cells were removed by incubation with anti-Thy 1.2 (30-H12) followed by rabbit complement (Pel-Freez Biologicals, Rogers, AR). The cells were then incubated with biotinylated anti-CD4 (GK1.5) and anti-CD8 (53-6.7) MAbs followed by streptavidin-conjugated microbeads and were passed through the magnetic column. This procedure routinely resulted in !1% CD3 ϩ T cells. Culture conditions. For the stimulation of TT-specific CD4 ϩ T cells in vitro, TT was adsorbed to latex microspheres as described [5, 26] . Peyer's patch CD4 ϩ T cells ( cells/mL) were cultured 6 2 ϫ 10 with T cell-depleted, irradiated splenic feeder cells ( cells/ 6 2.5 ϫ 10 mL) from naive mice in complete medium (RPMI 1640; Cellgro Mediatech, Washington, DC) containing 10% fetal calf serum, 1% L-glutamine, 50 mM 2-mercaptoethanol, 10 mM HEPES, 100 U/ mL penicillin, 100 mg/mL streptomycin, and 40 mg/mL gentamicin. The cultures were supplemented with 10 U/mL mouse rIL-2 (Genzyme, Cambridge, MA). About 5 TT-coated particles/CD4 ϩ T cell induced optimal T cell proliferation and cytokine production. Control wells consisted of cells only, latex beads only, and latex beads added to feeder cells. CD4 ϩ T cell cultures were incubated for 4 days at 37ЊC in 5% CO 2 in air.
To examine the effect of LT or CT on increased expression of costimulatory molecules on B cells and macrophages, T celldepleted Peyer's patch cells were stimulated with either LT or CT. An aliquot of cells ( cells/mL) was incubated in mm 6 1 ϫ 10 12 ϫ 75 polypropylene tubes (Falcon; Becton Dickinson Labware, Franklin Lakes, NJ) to avoid spontaneous activation of macrophages by adherence during the incubation period. One microgram of LT or CT was added to these cultures and incubated for 20 h. In some experiments, T cell-depleted Peyer's patch cells were incubated with LT or CT in the presence of anti-CD40 MAb (0.1-1.0 mg/mL; PharMingen, San Diego). After incubation, cells were removed, washed extensively, and then double-stained with either fluorescein isothiocyanate-conjugated anti-B220 or anti-Mac-1 and biotinylated anti-B7-1 (1G10) or anti-B7-2 (GL1) (PharMingen) followed by streptavidin-phycoerythrin (PharMingen). Labeled cells were then analyzed by flow cytometry (FACScan; Becton Dickinson). To assess the costimulatory effects of B7-1 and B7-2 induced by LT or CT on CD4 ϩ T cells in vitro, T cell-depleted Peyer's patch cells were pretreated with LT or CT. After incubation for 20 h, cells were washed in PBS and fixed with 0.5% paraformaldehyde. Peyer's patch CD4 ϩ T cells ( /mL) isolated from IL-4 ϩ/ϩ or 6 2 ϫ 10 IL-4 Ϫ/Ϫ mice were incubated with T cell-depleted Peyer's patch cells treated with LT or CT for 3 days at 37ЊC in 5% CO 2 in the presence of 100 ng/mL immobilized anti-CD3 MAb. In some experiments, MAbs to B7-1 (10 ng/mL) or B7-2 (10 ng/mL) were added to the cultures. To assess the effect of LT and CT on CD4 ϩ T cells in vitro, Peyer's patch CD4 ϩ T cells ( /mL) were isolated and 6 2 ϫ 10 incubated with 1 ng/mL LT or CT in the presence of 1 mg/mL immobilized anti-CD3 MAb for 72 h.
Analysis of secreted cytokines. Cytokine levels in culture supernatants were determined by a cytokine-specific ELISA as described elsewhere [12, 19] . In brief, 96-well plates (Nalge Nunc International, Naperville, IL) were coated with monoclonal anti-
anti-IL-10 (JES5-2A5) (PharMingen). After blocking, samples and serial 2-fold dilutions of standards were added to duplicate wells and incubated overnight at 4ЊC. The wells were washed and incubated with biotinylated monoclonal anti-IFN-g (XMG 1.2), anti-IL-2 (JES6-5H4), anti-IL-4 (BVD6-24G2), anti-IL-5 (TRFK-4), anti-IL-6 (MP5-32C11), or anti-IL-10 (JES5-16E3) (PharMingen) MAbs. After incubation, peroxidase-labeled anti-biotin antibody (Vector Laboratories, Burlingame, CA) was added and developed with 2,2 -azinobis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) containing H 2 O 2 (Moss, Pasadena, MD). Standard curves were generated by use of mouse rIFN-g, rIL-5, rIL-6 (Genzyme), rIL-2 (PharMingen), rIL-4 (Endogen, Boston), and rIL-10 (R&D Systems, Minneapolis). The ELISA could detect 1 U/mL IFN-g, 0.2 U/mL IL-2, 10 pg/mL IL-4, 2 U/mL IL-5, 1 ng/mL IL-6, and 0.5 ng/mL IL-10.
Quantitative analysis of cytokine-specific mRNA. For evaluation of cytokine-specific mRNA levels, a quantitative reverse-transcriptase (RT) polymerase chain reaction (PCR) was used. Total RNA was isolated by the acid-guanidinium thiocyanate-phenolchloroform extraction procedure. Cytokine-specific rDNA for IFN-g, IL-2, IL-4, IL-5, IL-6, IL-10, and b-actin were used as internal standards as described in detail elsewhere [3, 27] with minor modifications. In brief, aliquots of total RNA were subjected to standard RT. RT products with a series of diluted rDNA internal standards were amplified by PCR. For quantification, capillary electrophoresis with the laser-induced fluorescence detection system (LIF-P/ACE; Beckman Instruments, Fullerton, CA) was applied as described elsewhere [28, 29] . In brief, PCR products were analyzed by means of a coated capillary tube in Tris-borate-EDTA containing replaceable linear polyacrylamide and fluorescent intercalator. The fluorescence content of each cytokine-specific RT-PCR product was expressed as the peak area of relative fluorescence light units. Plotting of peak areas versus the serial dilutions of rDNA internal standard or sample RNA resulted in a linear relationship.
Detection of antigen-specific antibody isotype and IgG subclass responses. Fecal extracts for antibody analysis were obtained by vortexing fecal pellets in PBS [25] . Antibody titers in serum and fecal extracts were determined by ELISA as described elsewhere [25] . In brief, plates were coated with TT (5 mg/mL) or ovalbumin (1 mg/mL) and blocked by 10% goat serum in PBS. After washing, serial dilutions of serum or fecal extracts were added in duplicate.
After incubation, the plates were washed, peroxidase-labeled goat anti-mouse g or a heavy chain-specific antibodies (Southern Biotechnology Associates, Birmingham, AL) were added to appropriate wells, and ABTS with H 2 O 2 (Moss) was then added for color development. For IgG subclass analysis, biotinylated rat monoclonal anti-mouse g1 (G1-7.3), g2a (R19-15), g2b (R12-3), or g3 (R40-82) heavy chain-specific antibodies (PharMingen) and streptavidin-conjugated peroxidase were used. End point titers were expressed as the reciprocal log 2 of the last dilution that gave an optical density at 414 nm of 10.1 above those obtained with unimmunized mouse groups after 15 min of incubation.
Analysis of total and antigen-specific IgE levels. Total IgE was measured by standard ELISA and antigen-specific IgE responses were examined by IgE-capture ELISA with use of luminometry [30, 31] . In brief, 96-well plates (Dynatech Microlite, Chantilly, VA) were coated with anti-mouse IgE MAb (R35-72; PharMingen). After blocking with 3% bovine serum albumin in PBS, the samples were added in duplicate and incubated overnight at 4ЊC. For analysis of total IgE antibody levels, biotin-conjugated anti-IgE MAb (R35-92; PharMingen) was added to appropriate wells. For antigen-specific responses, biotinylated TT was added to the plates. After incubation of the biotinylated anti-IgE MAb or TT, the plates were washed with PBS-Tween containing EGTA and incubated with streptaequorin (Sealite Science, Bogard, GA). The plates were then washed with PBS-Tween-EGTA and air-dried. The wells containing the aequorin derivatives were developed in a luminometer (ML-3000; Dynatech) by injection of 100 mL of a buffer containing 20 mM calcium acetate in 50 mM Tris buffer (pH 7.5). The concentration of total IgE was determined with a standard curve obtained by use of purified mouse myeloma IgE. This method could detect as little as 400 pg/mL total serum IgE antibodies. End point titers of TT-specific IgE were determined as the dilution of each sample showing a 2-fold relative increase in light units above the background.
Antibody-forming cell assay. Lamina propria lymphocytes were isolated from small intestine by use of collagenase (type IV, 0.5 mg/ mL) after removal of intestinal intraepithelial lymphocytes [32] . To assess numbers of TT-specific antibody-forming cells, an enzymelinked immunospot assay was done as described elsewhere [25] . In brief, 96-well nitrocellulose plates (Millititer HA; Millipore, Bedford, MA) were coated with TT (5 mg/mL), and after incubation, plates were washed and blocked with 10% goat serum. The blocking solution was discarded, cells at various dilutions were added, and the cell suspensions were incubated for 4 h at 37ЊC in 5% CO 2 in moist air. The detection antibody consisted of goat anti-mouse a heavy chain-specific horseradish peroxidase-conjugated antibodies (Southern Biotechnology Associates). After overnight incubation, plates were washed with PBS and developed by addition of 3-amino-9-ethylcarbazole dissolved in 0.1 M sodium acetate buffer containing H 2 O 2 to each well. Plates were incubated at room temperature for 15-20 min and washed with water, and antibodyforming cells were counted with the aid of a stereo microscope.
Statistics. 1A, 1B) . These results revealed that CD4 ϩ T cells stimulated with anti-CD3 and LT were not dependent on IL-4 for the induction of IL-5, a Th2-type cytokine, whereas those stimulated with anti-CD3 and CT were.
Both LT and CT induce B7-2 expression on APC. We next addressed the possibility that B7-1 and B7-2 costimulatory molecules on APC could play an important role in the induction of distinctive patterns of Th1-and Th2-type responses when LT or CT was used as adjuvant. Therefore, we assessed the direct effect of LT or CT on expression of B7-1 and B7-2 by either B cells (B220 ϩ ) or macrophages (Mac 1 ϩ ) obtained from the Peyer's patches. For example, incubation of Peyer's patch cells with LT resulted in the up-regulation of B7-2, but not B7-1, expression on both B220 ϩ and Mac 1 ϩ cells. On the other hand, CT enhanced B7-2 and to a lesser extent B7-1 expression on both APC types (figure 2). To examine the effect of CD40-CD40 ligand (CD40L) cosignaling on B7 expression induced by LT or CT, anti-CD40 MAb was added to the cultures containing APC and either LT or CT. However, signaling via CD40 was not involved, because anti-CD40 MAb treatment did not affect costimulatory B7 expression (figure 2). Further, both LT and CT induced B7 expression on B220 ϩ and Mac-1 ϩ cells isolated from CD40 Ϫ/Ϫ mice (data not shown). Because it has been shown that B7-2 appears earlier than B7-1 when B cells are activated [33] [34] [35] [36] [37] , we assessed costimulatory molecule expression on B220 ϩ or Mac 1 ϩ cells after 6, 12, 24, and 48 h of incubation. However, all time points showed patterns of B7-1 and B7-2 expression similar to that seen at 20 h of incubation (data not shown). Ϫ/Ϫ mice were stimulated with immobilized anti-CD3 MAb in the presence of LT-or CT-treated APC. Cocultivation of CD4 ϩ T cells with LT-or CT-treated APC revealed significantly higher proliferative responses than were induced by anti-CD3 MAb stimulation alone. Further, the addition of MAb to B7-2 resulted in a marked reduction in T cell proliferation. In contrast, anti-B7-1 MAb only slightly inhibited the response compared with that to isotype-matched control MAb ( figure  3 ). These results showed that both LT and CT induce B7-2 expression on APC to costimulate CD4 ϩ T cell proliferative responses when activated via the T cell receptor-CD3 complex. Cytokine analysis showed that when CD4 ϩ T cells isolated from IL-4 ϩ/ϩ mice were costimulated with LT-or CT-treated APC, this T cell subset produced significant levels of both Th1-(IFNg and IL-2) and Th2-type cytokines (IL-4 and IL-5) compared LT is also a mucosal adjuvant in IL-4 Ϫ/Ϫ mice. Previous studies showed that CT failed to serve as mucosal adjuvant in IL-4 Ϫ/Ϫ mice [12, 13] . Our in vitro study showed that IL-4 was not required for induction of Th2-type cytokine responses when CD4 ϩ T cells were stimulated with anti-CD3 MAb and LT but not CT. Thus, we sought to determine if oral delivery of TT and LT as mucosal adjuvant could induce TT-specific CD4 detectable total or TT-specific IgE levels compared with those in IL-4 ϩ/ϩ mice orally immunized with identical regimens (Table  1) . It was interesting to note that both total and TT-specific IgE antibody levels in IL-4 ϩ/ϩ mice orally immunized with TT plus LT were significantly lower than in mice given oral TT plus CT (Table 1) .
Cosignaling via B7-2 results in both Th1
LT induces both Th1-(IL-2 and IFN-g) and Th2-type cytokines (IL-5, IL-6, and IL-10) in IL-4
Ϫ/Ϫ mice. Because oral administration of TT plus LT induced TT-specific mucosal sIgA antibody responses in IL-4 Ϫ/Ϫ mice whereas oral TT plus CT did not, it was important to establish the nature of the CD4 ϩ T cells from IL-4 Ϫ/Ϫ mice orally immunized with TT plus CT produced only low levels of IL-6 with no detectable IL-5 or IL-10 ( figure 7) .
The Th1 and Th2 cytokine patterns were further analyzed at the transcriptional level by cytokine-specific quantitative RT-PCR. Increased levels of IFN-g-and IL-2-specific mRNA were present in TT-stimulated CD4 ϩ T cell cultures from IL-4 ϩ/ϩ and IL-4 Ϫ/Ϫ mice orally immunized with TT plus LT compared with those in mice given TT plus CT, a finding in complete agreement with the levels of secreted Th1 cytokines (figure 7). As expected, no IL-4-specific mRNA was detected; however, IL-5-, IL-6-, and IL-10-specific mRNA was induced in TT-specific CD4 ϩ T cells from IL-4 Ϫ/Ϫ mice orally immunized with TT plus LT. In contrast, no IL-5-or IL-10-and only low levels of IL-6-specific mRNA were detected in TT-specific CD4 ϩ T cells from IL-4 Ϫ/Ϫ mice orally immunized with TT plus CT ( figure 7 ). Taken together, these studies show that oral administration of TT plus LT as adjuvant induces both Th1-type cells, which secrete IFN-g and IL-2, and Th2-type cells, which produce IL-5, IL-6, and IL-10, in Peyer's patches of IL-4 Ϫ/Ϫ mice.
Discussion
This study has systematically analyzed the mechanisms to explain differences noted when LT or CT are used as mucosal adjuvants. Our results show that whereas CT as mucosal adjuvant elicits classical IL-4-mediated Th2-type responses, the adjuvant LT does not require IL-4 for induction of other Th2-type cytokines that support mucosal IgA responses. Thus, to discern why LT induces CD4
ϩ Th1-and largely IL-4-independent Th2-type responses but CT elicits predominant Th2-type responses, we initiated studies to explore direct effects of these enterotoxins on CD4 ϩ T cells. Our results showed that CT directly affected CD4 ϩ T cells activated via T cell receptor-mediated signaling with selective inhibition of Th1-type responses. This finding completely agrees with previous studies [6, 23] . On the other hand, LT tended to maintain Th1-type responses; however, significant inhibition of IL-4 production was noted when CD4 ϩ T cells from normal mice were stimulated with this enterotoxin. This indicates that LT directly inhibits IL-4 gene expression without effects on Th1-type cytokines.
Of interest was the finding that LT maintained similar levels of IL-5 production in IL-4 Ϫ/Ϫ and IL-4 ϩ/ϩ mice. It is likely that an alternative Th2 cytokine pathway that does not require IL-4 production exists for LT. In this regard, previous studies have suggested that LT may open a novel activation cascade for stimulation of Th1-type responses by the signals through subunit LT-B-specific responses because LT-B binds ganglioside GM1 as well as GM2 and asialo-GM1, whereas CT-B only binds ganglioside GM1 [7, [33] [34] [35] . Thus, LT may affect CD4 To this point, our results show that although IL-4 is required for CT-mediated Th2-type responses, LT supports Th1-and IL-4-independent Th2-type responses. However, it is still unclear how these enterotoxins enhance antibody responses. Thus, in the second series of experiments, we explored the effects of LT and CT on B7-1 and B7-2 expression, because previous studies have shown that these costimulatory molecules are involved in the adjuvant effects of CT [21] [22] [23] . Our results showed that LT enhanced B7-2 on Peyer's patch B cells and macrophages and CT up-regulated B7-2 and, to a lesser extent, B7-1. Further, the stimulatory effects of LT and CT on B7 expression were independent of CD40-CD40L cosignaling. Interestingly, however, oral immunization of CD40 Ϫ/Ϫ mice with LT or CT as adjuvant failed to elicit mucosal IgA and serum IgG antibody responses to coadministered protein. In this regard, several studies have shown that CD40L-deficient mice fail to elicit antigen-specific humoral immune responses to immunization with a thymus-dependent antigen [36, 37] . Thus, although CD40-CD40L cosignaling is not directly involved in the effects of LT and CT on B7 up-regulation on APC, this is an essential signal for initiation of T cell-dependent antigenspecific antibody responses.
Both LT-and CT-treated APC enhanced proliferative responses in CD4
ϩ T cells when stimulated with anti-CD3 MAbs. These results imply that LT and CT induce B7-2 and B7-1/B7-2, respectively, on APC that in turn lead to costimulation of CD4 ϩ T cells activated via the T cell receptor-CD3 complex. In support of this hypothesis, enhanced T cell proliferative responses were blocked by anti-B7-2 MAb, indicating that B7-2 expression induced by LT or CT was a major factor for enhancement of CD4 ϩ T cell responses and thus for adjuvanticity of LT and CT. In contrast, anti-B7-1 treatment of CT-treated APC only slightly inhibited this costimulatory effect. In this regard, it was shown that although CT enhances both B7-1 and B7-2 on B cells, the extent of the increase in B7-1 was much smaller than for B7-2 [21] . Further, costimulatory effects induced by CT-treated macrophages were blocked by anti-B7-2 but not by anti-B7-1 MAbs [22] . Our recent study has also shown that both nontoxic mutant and native CT induce B7-2 and, to a lesser extent, B7-1 on mucosal B cells and macrophages, with subsequent costimulatory activity. This effect was inhibited by anti-B7-2 but not anti-B7-1 [23] . In that study, we suggested that because the percentage of increase in B7-1 induced by CT was relatively low, the costimulatory effect of B7-1 was below the threshold required to support T cell responses. These studies together with our present results now suggest that both LT and CT induce mainly B7-2 expression on APC for subsequent costimulatory signaling to CD4 ϩ T cells and thus partially explain why both molecules are effective adjuvants.
Whether the effect of LT and CT on APC and CD4 ϩ T cells is mediated by a cAMP-dependent pathway is not clear. However, because LT and CT both retain ADP-ribosyltransferase activity [38] , it is unlikely that signals via a cAMP-pathway promote distinct Th1 and Th2 cytokine responses when LT or CT are used. In this regard, our recent study has clearly shown that a mutant CT that lacks ADP-ribosyltransferase activity enhanced B7-2 expression of APC that in turn led to enhanced proliferative responses of CD4 ϩ T cells. Further, mutant CT preferentially inhibited Th1-type cytokine responses [23] . These results suggest that the production of intracellular cAMP is not required for the effects on APC and T cells when LT or CT is used as adjuvant.
The use of CD4 ϩ T cells from IL-4 Ϫ/Ϫ mice provided us with an opportunity to firmly establish that B7-2 costimulation enhanced IL-4-mediated Th2-type responses. Previous studies have shown that both B7-1 and B7-2 molecules enhance Th1 and Th2 cytokines [39] [40] [41] . In contrast, other studies have suggested that IL-4 produced by T cells is dependent on B7-2, but not B7-1, costimulation [42] [43] [44] . In this study, our results revealed that B7-2 induced by LT or CT possessed costimulatory activity and elicited both Th1-and Th2-type cytokine re- ϩ T cells ( /mL) were isolated from Peyer's patches of mice and were cultured with TT-coated latex beads (1:5) in the presence 6 2 ϫ 10 of irradiated, T cell-depleted splenic feeder cells ( /mL) and IL-2 (10 U/mL). Th1-and Th2-type cytokine molecules per nanogram of 6 2.5 ϫ 10 total RNA were determined by quantitative reverse-transcriptase (RT) polymerase chain reaction (PCR) analysis that used competitive rDNA and capillary electrophoresis with a laser-induced fluorescence detection system. Culture supernatants were harvested and analyzed for elucidation of secreted cytokines by respective cytokine-specific ELISA. Results are expressed as mean ‫ע‬ SE from 5 mice per group from total of 3 separate experiments.
sponses; however, CD4 ϩ T cells from IL-4 Ϫ/Ϫ mice that were treated in an identical manner supported only Th1-type cytokine responses. These results suggest that the adjuvant responses induced by LT and CT are due in part to B7-2 costimulation and to IL-4-mediated Th2 responses.
Our in vivo studies provide support to the in vitro results discussed above. As expected from earlier studies [12, 13] , CT failed to support antigen-specific mucosal IgA responses in IL-4 Ϫ/Ϫ mice. On the other hand, oral immunization with TT together with LT as adjuvant elicited TT-specific CD4 ϩ T cells producing Th1 and IL-4-independent Th2 cytokines with subsequent mucosal IgA antibodies in IL-4 Ϫ/Ϫ mice. Thus, both the in vitro and in vivo results in the present study support the notion that LT functions directly at the level of CD4 ϩ T cells and opens a signal transduction pathway for IL-5, IL-6, and IL-10 to promote mucosal sIgA responses in the absence of classical Th2-type cells producing IL-4, by an as-yet-uncharacterized IL-4-independent pathway.
It should also be emphasized that neither IgG1 nor IgE antigen-specific antibodies were induced in IL-4 Ϫ/Ϫ mice given oral antigen plus LT or CT as adjuvant. These findings lend further support to the evidence that IL-4 is a key cytokine for induction and regulation of antigen-specific IgG1 and IgE responses. On the other hand, our studies show that IL-4 is not strictly required for IgA responses; however, IL-5, IL-6, and IL-10 appear to be important for mucosal IgA immunity. It is tempting to suggest that the LT-induced IL-4-independent Th2-type response is a major pathway for mucosal IgA antibody responses. In support of this, several studies have shown that CD4 ϩ T cells from the gastrointestinal tract spontaneously secrete IFNg, IL-5, and IL-6 [32, [45] [46] [47] . Thus, we predict that CD4 ϩ T cells producing IL-5 and IL-6 (mucosal Th2-type) in addition to those secreting IL-4 (classical Th2-type) are required for optimal mucosal IgA synthesis.
In summary, our study shows that, whereas adjuvants such as CT are most effective for generating mucosal IgA responses by inducing IL-4-dependent Th2-type responses, LT signals both Th1-and Th2-type responses. Furthermore, this LT-induced Th2 cytokine pathway is largely IL-4-independent.
